0
Clinical Investigations: PLEURAL DISEASE |

A Retrospective Analysis of the Management of Parapneumonic Empyemas in a County Teaching Facility From 1992 to 2004*

Glena Cheng, MD; Janine R.E. Vintch, MD
Author and Funding Information

*From the Division of Respiratory and Critical Care, Physiology and Medicine, Kaiser Permanente, Torrance, CA.

Correspondence to: Glena Cheng, MD, Department of Pulmonary and Critical Care, Kaiser-Permanente, Bellflower Medical Center, 9400 E. Rosecrans Avenue, Bellflower, CA 90706; e-mail: glenacheng@hotmail.com



Chest. 2005;128(5):3284-3290. doi:10.1378/chest.128.5.3284
Text Size: A A A
Published online

Objectives: To characterize how patients with empyemas are managed initially at our facility and to determine how “less aggressive” treatments (eg, no drainage, repeat thoracentesis, or tube thoracostomy) affect short-term outcomes (ie, inpatient mortality and the need for a second intervention) compared to “more aggressive” treatments (eg, intrapleural fibrinolytic agents, video-assisted thoracoscopic surgery, or other surgery). We will also assess whether earlier diagnosis, earlier antibiotic treatment, fewer patient comorbidities, and consulting appropriate services improve mortality.

Design: Retrospective chart analysis.

Setting: County teaching hospital in Los Angeles, CA.

Patients: Seventy-two adult inpatients with parapneumonic empyemas.

Interventions: Mortality and the need for second intervention rates were calculated and compared with data published in the 2000 American College of Chest Physicians consensus statement on the management of parapneumonic effusions using the Fisher exact test. Comparisons were made between empyema survivors and nonsurvivors using t tests and χ2 tests.

Results: All 72 patients were managed with less aggressive initial treatments. There were no differences in mortality when our patients were compared to the less aggressive group from the literature (6% vs 9%, respectively; p = 0.40; relative risk, 0.6; 95% confidence interval [CI], 0.23 to 1.62) or the more aggressive group from the literature (6% vs 3%, respectively; p = 0.29; relative risk, 1.8; 95% CI, 0.64 to 5.23). There was no difference between the second intervention rate of our patients and that of the less aggressive group from the literature (47% vs 43%, respectively; p = 0.47; relative risk, 1.1; 95% CI, 0.86 to 1.42), although there was a difference when compared to the more aggressive group (47% vs 11%, respectively; p < 0.0001; relative risk, 4.5; 95% CI, 3.20 to 6.31). There were no statistically significant differences in time of diagnosis, the timing of antibiotic treatment, the number of patient comorbidities, or the number of services consulted when survivors and nonsurvivors from the study were compared.

Conclusions: Patients with empyemas at our hospital are treated with less aggressive initial treatments and have a higher second intervention rate when compared to patients described in the literature who were initially managed with more aggressive treatments.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Topics

empyema

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543